A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Alendronic acid/guanidine dextran conjugate (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors DexTech Medical
- 01 Dec 2016 Results published in the Anticancer Research
- 13 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Mar 2013 Planned End Date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.